However, the small number of patients in this study along with the multiple parameters influencing tumour targeting in RIT in CD20+ lymphoma do not allow drawing definitive conclusions concerning the optimal treatment approach in RIT to be drawn, and this should be the basis of further studies. This evidence concerns the gene MS4A1 and lymphoma.